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INTRODUCTION  
Ceftriaxone  sodium  (Figure 1)   is  chemically  
(6R,7R)-7- [[(2Z)-(2-amino-4-
thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-
[[(1,2,5,6-tetrahydro-2-methyl-5,6-ioxo-1,2,4-tria- zin-
3-yl)thio]-methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylic acid 
1
. Ceftriaxone is a third generation, 
semi- synthetic cephalosporin antibiotic. 
Cephalosporins are deri- vatives of 7-
aminocephalosporic acid and are closely rela- ted to 
penicillins in structure. Ceftriaxone sodium is a long 
acting, broad-spectrum  cephalosporin antibiotic for 
pare- nteral use. The bactericidal activity of ceftriaxone 
sodium results from inhibition  of cell wall synthesis. 
It exerts in vitro activity against a wide range of 
Gram-negative and Gram-positive microorganisms. It 
is highly stable to most beta-lactamases, both 
penicillinases and cephalosporinases, of Gram-positive 
and Gram-negative bacteria. A thorough  literature 
survey has revealed that  HPLC method for 
ceftriaxone sodium with combination of other drugs 
and  individually in dosage forms 
2-5
, microbia 
bioassay methods 
6, 7
, and spectrophotometric methods 
in dosage forms 
8–12
 have been reported for analysis of 
ceftriaxone sodium. Costlier and volatile solvents were 
used as mobile phase solvent system and the time of 
analysis was more in some reported methods. Some 
spectrophotometric  methods are recently descri- bed 
in the literature for analysis of drugs in raw material and 
finished products such as ceftazidime 
13–15
, cefuroxime 
, and cefazolin . These spectrophotometric methods 
involve the use of no toxic organic solvents, which do 
not contribute  to the generation of this kind of waste 
by the chemicals or industries. In this context, 
spectrophotometry stands out. Therefore, the trend is 
that the industries look for ways to reduce the 
impacts of their  activities on  the environment. So, the 
principle objective of this study was, therefore, to 
develop a simple, selective, precise, less time 
consuming, and economical method with a wide linear 
range and good sensitivity for assay of ceftriaxone 
sodium in the powder for injection dosage forms. The 
parent drug stability guidelines issued by the interna- 
tional conference of harmonization (ICH)  require that 
analytical test procedure should indicate stability. 
Therefore, the present study was extended to establish 
the inherent sta- bility of ceftriaxone sodium under 
different stress conditions such as, alkaline, acidic, 
oxidative, and photolytic conditions. Thus, this method 
can be utilized to compare the results for the content 
analysis of stability samples, since the purpose of 
stability studies is to monitor possible changes to a 
product or a material over a time at different storage 
conditions. 
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ABSTRACT 
A simple, accurate rapid and precise RP-HPLC method has been developed and validated for determination of Ceftriaxone in 
bulk drug. The RP-HPLC separation was achieved on Promosil C-18, (250 mm, 4.6 mm, 5µm) using mobile phase buffer: 
methanol ph 6.8 (90: 10 v/v) at flow rate of 1.0 ml/min at ambient temperature. The retention times were 7.111 min. for 
Ceftriaxone. Calibration plots were linear over the concentration range 1-20µg/ml. Quantification was achieved with 
photodiode array detection at 260 nm over the concentration range of 1-50 µg/ml. The method was validated statistically and 
applied successfully for the determination of Ceftriaxone. Validation studies revealed that method is specific, rapid, reliable, 
and reproducible. The high recovery and low relative standard deviation confirm the suitability of the method for the routine 
determination of Ceftriaxone in bulk drug. 
Keywords    Ceftriaxone, Water, Buffer, Validation, HPLC. 
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Figure 1: Chemical structure of Ceftriaxone Sodium 
 
MATERIALS AND METHODS  
All the reagents used were of HPLC grade and 
analytical grade and were purchased from Merck 
Chemicals, India. Reference standard of Ceftriaxone 
was supplied as gift sample from Sun Pharmaceutical 
Laboratories Limited, Mumbai with purity of 99.987%. 
 Preparation of buffer solution:  
Mix 5mL of glacial acid in 1000mL of milli Q water. 
To 1000mL of 5mL glacial acetic acid solution, add 
0.94gm of 1-Hexane sulphonic acid anhydrous.sonicate 
to dissolve. 
 Preparation of Mobile phase: 
The mobile phase is prepared by mixing buffer: 
methanol in the ratio of 90:10 Filtered and degas it 
 Chromatographic Run: 
Load the standard solution of Ceftriaxone in the 
injector, enter the HPLC parameters as per (Table: 1), 
save the method, inject and run for 20min.
  
Table 1: Chromatographic conditions for the optimized method for Ceftriaxone 
S. No. Parameters Description 
1. Instrument  A HPLC instrument (Labtronics)  with Model 3201  
2. Column   Promosil C-18, (250 mm, 4.6 mm, 5µm) 
3. Mobile Phase  Mix 5ml of glacial acid in 1000ml of water. To 1000ml of 5ml glacial acetic 
acid solution, add 0.94gm of 1-Hexane sulphonic acid anhydrous. Sonicate to 
dissolve. The mobile phase is prepared by mixing buffer: methanol in the ratio 
of 90:10 Filtered and degas it. 
4. Flow Rate   1.0 mL/minute 
5. Detection wavelen  260 nm 
6. Injection Volume    10L 
7. Run Time  20 Minutes 
 
 
 Standard preparation of Ceftriaxone 
Accurately weigh and transfer about 20 mg of drug 
Ceftriaxone working standard into 100mL volumetric 
flask, and about 70 mL of diluents, sonicate to dissolve, 
dilute to volume with diluents and mix. Filter the 
solution through0.45µm. 
 Preparation of system suitability solution8. 
Accurately weigh and transfer about 10mg of working 
standard into 100ml volumetric flask. Add 25mL of 
0.1N HCl and 25mL of Diluent. Sonicate to dissolve. 
Keep the sample at about 80 °C. For 4 hours. Use this 
solution as system suitability solution. 
 Preparation of placebo solution8 
Accurately weigh and transfer powdered content of 
placebo equivalent to 100mg of Drug into 100 mL 
volumetric flask. Add about 70 mL diluent and sonicate 
for about 15 min. dilute to the volume and mix. Filter 
the solution through 0.45µm filters.  
 Preparation of diluent  
Use mobile phase as diluents {Mobile phase is Buffer: 
Methanol (90:10)} 
 
 
  Figure 2: Representive chromatograms of standard solution of Ceftriaxone 
Mobile phase = Buffer: Methanol (90:10) 
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METHOD VALIDATION 
The developed method was validated according to ICH 
guidelines. Standard calibration curve were prepared in 
the mobile phase with 5 concentration ranging from 1-
50 µg/ml for Ceftriaxone is injected in to HPLC system 
keeping the injection volume constant. The peak area 
was plotted against the corresponding concentration to 
obtain the calibration graphs. To study the reliability 
and suitability of developed method, recovery 
experiments were carried out at three levels 80, 100 and 
120%. Known concentration of Commercial tablet is 
spiked with known amounts of Ceftriaxone. At each 
level of the amount six determinations were performed 
and the results obtained were compared with expected 
results. Recovery for pharmaceutical formulations 
should be within the range 100±5%. The percent R.S.D 
of individual measurements was also determined. 
Precision of the assay was determined by repeatability 
(intra-day) and intermediate precision (inter-day) for 3 
consecutive days. Three different concentration of 
Ceftriaxone were analysed in six independent series in 
the same day (intra-day precision) and 3 consecutive 
days (inter-day precision). The repeatability of sample 
application and measurement of peak area for active 
compounds were expressed in terms of percent RSD. 
All chromatograms were examined to determine if 
compounds of interest co-eluted with each other or with 
any additional excipient peaks. Marketed formulation 
were analysed to determine the specificity of the 
optimized method in the presence of common tablet 
excipients. Limi of detection (LOD) and limit of 
quantitation (LOQ) were estimated from single to noise 
ratio. LOD and LOQ were calculated using 3.3/s and 
10/s formulae, respectively. Where  the standard 
deviation of the peak areas and s is is the slope of the 
corresponding calibration curve. To evaluate robustness 
of HPLC method a few parameters included variation of 
flow rate, percentage of buffer in the mobile phase, and 
pH of mobile phase. 
RESULT AND DISCUSSION  
 
The retention time of Ceftriaxone was peak eluted at 
7.111 min. The peaks are well separated with a 
resolution of 3.256 and Tailing 1.231. 
The mobile phase comprises of Buffer: Methanol 
(90:10) v/v  was selected as optimized mobile phase, 
because of the high purity, symmetry, proper tailing, 
high area and low RT value at same concentration as 
compared to other trail mobile phase. Furthermore, the 
stability of the drug in the mobile phase were also 
studied and result indicating that the drug Ceftriaxone 
was found to be stable during the storage time of 48 hr 
(Table 2). 
 
Table 2: Stability of the Ceftriaxone in the optimized mobile phase 
S. 
No. 
Storage conditions Mean area± SD 
(At zero hrs) 
 
SE 
Mean area± SD 
(At 48 hrs) 
 
SE 
1. Room Temperature 
 (25±0.5 
0
C) 
267438.3±2859.82 3474.9 248844.7±3650.63 2777.53 
2. Refrigerator 
(4±0.5 
0
C) 
252952.3±2859.82 3474.9 250011.3±3653.10 2778.63 
*Concentration of drug 10µg/ml in mobile phase. 
Linearity of the method was investigated by serially 
diluting the working standard to give a concentration 
range of 1-10 µm/ml and 20 µl from this was injected. 
The flow rate was maintained at 1 ml/min. temperature 
of column was kept ambient and the effluent was 
monitored at 260 nm. Calibration curve was constructed 
by plotting concentration against peak area (fig.3). 
 
 
Figure 3: Standard Curve of Ceftriaxone 
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The method was validated for linearity, precision, 
accuracy, specificity, limit of detection and limit of 
quantification as per ICH guidelines. All parameters are 
validated as per ICH guidelines.  
Optimum condition of mobile phases was investigated 
in the development of an HPLC method suitable for 
analysis of in the bulk drug. These included Methanol: 
Acetonitrile: Buffer (30:20:50) (% v/v), Methanol: 
Acetonitrile: Buffer (40:30:30), Methanol: buffer 
(50:50), Methanol: Buffer (60:40), Buffer: Methanol 
(80:20), and: Buffer: Methanol  (90:10).The same 
solvent mixture was used for extraction of the drug 
from the formulation containing excipients. The 
retention time of Ceftriaxone obtained was 7.0 ±.111 
(1). The system suitability tests for HPLC were carried 
out on freshly prepared solution of Ceftriaxone (10 
µg/ml) and parameters were studied. The results were 
summarized in Table 3. 
 
Table 3: System sutability test for Ceftriaxone: 
Sr. No. Parameter Value 
     1.  Retention time, min 7.000±0.111 
     2. Tailing factor 1.265±0.376 
    3. Asymmetry factor 1.165±0.876 
    4. Theoretical plates 5769±0.324 
    5. Resolution 2.678±0.879 
 
Assay of tablets of Ceftriaxone were perfomed. Twenty 
tablets of each company of strength 5 mg, 10 mg and 20 
mg were weighed and ground to a fine powder. A 
quantity of tablet powder equivalent to 10 mg of 
Ceftriaxone was transferred to 10 ml volumetric flask, 
dissolved and diluted with acetonitrile and water 
mixture to obtain 1 mg/ml. The solution was sonicated 
for 15 minute and filtered through 0.45 µm membrane 
filter. The solution was further diluted to obtain 
concentration 10 µm/ml. Peak area of the above 
prepared tablet solutions of Ceftriaxone were measured 
by using above mentioned chromatographic conditions 
and the amount of Ceftriaxone were found from 
regression equation (Table 4) &Recovery study (Table 
5).
 
Table 4: Results of Analysis of Commercial Tablets of Ceftriaxone 
Tablet  
Formulation 
Label claim(mg) % Label claim 
estimated*(Mean ± S.D.) 
% Coeff. Of 
Variation 
Standard  error 
I(OFRAMAX) 250 99.325 ± 1.435 1.543 0.465 
II(MONOCEF) 500 99.745 ± 1.406 1.435 0.845 
III (ROCEPHIN) 1000 99.854 ±1.457 1.506 0.687 
*Average of six determinations 
Table 5: Recovery Studies of Commercial Tablets of Ceftriaxone 
Tablet 
Formulation 
Label 
claim 
(mg) 
Drug added 
(mg) 
% Label claim 
estimated*(Mean ± S.D.) 
% Coeff. Of 
Variation 
Standard error 
I(OFRAMAX) 250 200 99.456 ± 1.534 1.658 0.543 
II(MONOCEF) 500 500 99.654 ± 1.453 1.549 0.654 
III 
(ROCEPHIN) 
1000 1250 99.546 ±0.658 0.732 0.659 
*Average of six determinations 
 
The linear regression date showed a good linear 
relationship over the concentration range of 1-50 µg/ml 
as summarized in Table 6. The limit of detection (LOD) 
and the limit of quantification(LOQ) of the drug were 
found by scanning the solution of Ceftriaxone having 
different lower concentrations and the LOD and LOQ 
were found to be 0.5 and 1 µg/ml indicates that method 
is sensitive (Table 6). The intraday and interday 
precision were determined by analyzing standard 
solution of Ceftriaxone at three different concentration 
levels (6, 8, 10 µg/ml). The % RSD for intraday and 
interday precision was found to be 0.376 – 0.975% and 
0.546-1.260% respectively which indicate that method 
is precise (Table 6). Repeatability of the method was 
studied by injecting 10 µg/ml solution of Ceftriaxone 
for six times and peak area was measured and % RSD 
was calculated which was found to be 0.198 shows 
repeatability of the method (Table 6). Accuracy of the 
method was evaluated by standard addition method in 
which appropriate portion of stock solutions of 
Ceftriaxone were spiked into blank placebo matrix to 
produce concentrations of 80 100 and 120% of 
theoretical concentration. The mean recovery of spiked 
samples obtained was in range of 99.45 to 99.65 reveals 
no interference of excipients and shows that method is 
accurate (Table 6).  
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Table 6: Stastiscal Data & Regression Equation for Ceftriaxone 
Validation Parameters Acceptance Crieteria 
Accuracy/ Recovery Recovery 98- 102% (individual) 
Precision RSD < 2% 
Repeatability RSD < 2% 
Intermediate Precision RSD < 2% 
Specificity/ Selectivity No interference, the peak purity index > 0.999 
Linearity Correlation coefficient r
2 
> 0.999 or 0.995 
Solution Stability > 12 hour 
Lower Detection Limit S/N > 2 or 3 
Lower Quantitation Limit S/N > 10 
 
The proposed validated method was successfully 
applied to determine Ceftriaxone in tablet form. The 
results obtained for tablets of Ceftriaxone were 
comparable with the corresponding labeled amounts 
(0.5 mg/tab) (table 4). Robustness of the method was 
estimated by changing the mobile phase composition 
(3±3), wavelength ±1 nm, injection  volume (20±2µl), 
column temperature (40±3
0
) and RSD values for all 
these changes calculated were less than 2 indicate that 
proposed method is robust. The proposed RP-HPLC 
method was accurate, precise, sensitive and rapid. The 
method also can be extended for the routine analysis of 
Ceftriaxone in tablet dosage form.  
 
CONCLUSION  
It is thus concluded that the proposed method is new, 
simple, cost effective, accurate, safe, free from pollution 
and precise and can be successfully employed in the 
routine analysis of these drugs in pharmaceutical dosage 
forms. The proposed method shall prove equally 
effective to analyze Ceftriaxone in the corresponding 
drug sample and may prove to be of great importance in 
pharmaceutical analysis. 
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